Btla fusion protein agonists and uses thereof
AssigneesSanford Burnham Prebys Medical Discovery Institute, Pfizer Inc.
InventorsCarl F. WARE, John SEDY, Tigran AIVAZIAN, Brian MILLER, Natasha K. CRELLIN
Life of this patent
Estimating the term…
Abstract
The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
Claims28
A fusion protein comprising a non-naturally occurring herpesvirus entry mediator (HVEM) protein and an Fc protein, wherein the fusion protein comprises an extracellular domain of the HVEM protein and the Fc protein.
7-9. (canceled)
A pharmaceutical composition comprising a fusion protein comprising a non-naturally occurring herpesvirus entry mediator (HVEM) protein and an Fc protein and a pharmaceutically acceptable carrier.
(canceled)
14-15. (canceled)
17-19. (canceled)
A method of treating a BTLA related disorder comprising administering a fusion protein comprising a non-naturally occurring HVEM protein and an Fc protein to a subject in need thereof, thereby treating the BTLA related disorder.
21-22. (canceled)
24-26. (canceled)
28-33. (canceled)
36-68. (canceled)
A herpesvirus entry mediator (HVEM) protein comprising mutations S58R, G68T, L70W and L90A.
Dependencies are inferred from the claim text.